BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33402452)

  • 1. Contemporary Molecular Classification of Urinary Bladder Cancer.
    Goutas D; Tzortzis A; Gakiopoulou H; Vlachodimitropoulos D; Giannopoulou I; Lazaris AC
    In Vivo; 2021; 35(1):75-80. PubMed ID: 33402452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
    Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
    EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Subtypes of Bladder Cancer.
    McConkey DJ; Choi W
    Curr Oncol Rep; 2018 Aug; 20(10):77. PubMed ID: 30128829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution of bladder cancer genomics: What have we learned and how can we use it?
    Audenet F; Attalla K; Sfakianos JP
    Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications.
    Minoli M; Kiener M; Thalmann GN; Kruithof-de Julio M; Seiler R
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathology of the luminal class of urothelial tumors.
    Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
    J Pathol; 2019 Nov; 249(3):308-318. PubMed ID: 31232464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder cancer genomics.
    Siracusano S; Rizzetto R; Porcaro AB
    Urologia; 2020 May; 87(2):49-56. PubMed ID: 31942831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Subtyping in Bladder Cancer.
    Jalanko T; de Jong JJ; Gibb EA; Seiler R; Black PC
    Curr Urol Rep; 2020 Mar; 21(2):9. PubMed ID: 32166460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility.
    Warrick JI; Al-Ahmadie H; Berman DM; Black PC; Flaig TW; Höglund M; Bubendorf L; van der Kwast TH; Cheng L;
    Am J Surg Pathol; 2024 Jan; 48(1):e32-e42. PubMed ID: 37199442
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Kacew A; Sweis RF
    Front Immunol; 2020; 11():575258. PubMed ID: 33224141
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
    Choi W; Ochoa A; McConkey DJ; Aine M; Höglund M; Kim WY; Real FX; Kiltie AE; Milsom I; Dyrskjøt L; Lerner SP
    Eur Urol; 2017 Sep; 72(3):354-365. PubMed ID: 28365159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.
    Choi W; Czerniak B; Ochoa A; Su X; Siefker-Radtke A; Dinney C; McConkey DJ
    Nat Rev Urol; 2014 Jul; 11(7):400-10. PubMed ID: 24960601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
    Lang H; Béraud C; Cabel L; Fontugne J; Lassalle M; Krucker C; Dufour F; Groeneveld CS; Dixon V; Meng X; Kamoun A; Chapeaublanc E; De Reynies A; Gamé X; Rischmann P; Bieche I; Masliah-Planchon J; Beaurepere R; Allory Y; Lindner V; Misseri Y; Radvanyi F; Lluel P; Bernard-Pierrot I; Massfelder T
    Front Oncol; 2022; 12():930731. PubMed ID: 36033544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The urothelial cell line UROtsa transformed by arsenite and cadmium display basal characteristics associated with muscle invasive urothelial cancers.
    Hoggarth ZE; Osowski DB; Freeberg BA; Garrett SH; Sens DA; Sens MA; Zhou XD; Zhang KK; Somji S
    PLoS One; 2018; 13(12):e0207877. PubMed ID: 30550540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.
    Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ
    Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic subtypes of invasive bladder cancer.
    McConkey DJ; Choi W; Dinney CP
    Curr Opin Urol; 2015 Sep; 25(5):449-58. PubMed ID: 26218634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Pathologic Subtyping of Urothelial Bladder Carcinoma in Young Patients.
    Shelekhova KV; Krykow KA; Mescherjakov IA; Mitin NP
    Int J Surg Pathol; 2019 Aug; 27(5):483-491. PubMed ID: 30854907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts.
    Sjödahl G; Jackson CL; Bartlett JM; Siemens DR; Berman DM
    J Pathol; 2019 Apr; 247(5):563-573. PubMed ID: 30604486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.